title: [Hematological toxicity of radioimmunotherpy with 90Y Ibritumomab].
abstract: Radioimmunotherapy with 90Y Ibritumomabu (Zevalin, BSP) is a new method of systemic radiotherapy applicable to B-cell lymphoma patients. It may be delivered as a short outpatient procedure, with few adverse effects other than hematological toxicity. In the paper, we present length and depth of cytopenias, together with the results of additional tests performed to reveal the possible pathomechanisms, based on 102 patients treated at the University Hospital in Krakow.
authors: Katedra i Klinika Hematologii UJ CM w Krakowie. wojciech.jurczak@lymphoma.pl
authors: Wojciech
authors: W
authors: Jurczak
authors: Marta
authors: M
authors: Szostek
authors: Małgorzata
authors: M
authors: Jakóbczyk
authors: Anna Sowa
authors: AS
authors: Staszczak
authors: Dagmara
authors: D
authors: Zimowska-Curyło
authors: Agnieszka
authors: A
authors: Giza
authors: Marcin
authors: M
authors: Sobociński
authors: Alicja
authors: A
authors: Hubalewska-Dydejczyk
authors: Aleksander B
authors: AB
authors: Skotnicki
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D006402:Hematologic Diseases / Q000209:etiology*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000009:adverse effects*; D015021:Yttrium Radioisotopes / Q000009:adverse effects*
chemical_list: D000911:Antibodies, Monoclonal; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan